Recovery of the T-cell repertoire in CIDP by IV immunoglobulins

Neurology

Volumn 80, Issue 3, 2013, Pages 296-303

  Mausberg, Anne K ^a   Dorok, Mareike ^a   Stettner, Mark ^a   Müller, Matthias ^b   Hartung, Hans Peter ^a   Dehmel, Thomas ^a   Warnke, Clemens ^a   Zu Hörste, Gerd Meyer ^a   Kieseier, Bernd C ^a  

^a Department of Orthopedic Surgery   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; HUMAN IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OLIGOCLONAL BAND; RITUXIMAB; T LYMPHOCYTE RECEPTOR BETA CHAIN;

ADULT; AGED; ARTICLE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; HUMAN; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; MALE; PLASMAPHERESIS; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 84873681680     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31827debad     Document Type: Article

References (36)

1. Koller H, Kieseier BC, Jander S, et al. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 2005; 352:1343-1356.
2. Vallat JM, Sommer C, Magy L. Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition. Lancet Neurol 2010;9:402-412.
3. Dalakas MC. Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol 2011;7:507-517.
4. Kieseier BC, Kiefer R, Gold R, et al. Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 2004;30: 131-156. (Pubitemid 38982218)
5. Meyer zu Horste G, Hartung HP, Kieseier BC. From bench to bedside: experimental rationale for immune-specific therapies in the inflamed peripheral nerve. Nat Clin Pract Neu-rol 2007;3:198-211. (Pubitemid 46605271)
6. Misawa S, Kuwabara S, Mori M, et al. Serum levels of tumor necrosis factor-alpha in chronic inflammatory demyelinating polyneuropathy. Neurology 2001;56:666-669. (Pubitemid 32210005)
7. Hughes RA, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradic-uloneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 2008;7:136-144.
8. Durandy A, Kaveri SV, Kuijpers TW, et al. Intravenous immunoglobulins: understanding properties and mechanisms. Clin Exp Immunol 2009;158(suppl 1):2-13.
9. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001;345:747-755.
10. Rudolph MG, Stanfield RL, Wilson IA. How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol 2006;24:419-466.
11. Davis MM, Bjorkman PJ. T-cell antigen receptor genes and T-cell recognition. Nature 1988;334:395-402.
12. Gauss GH, Lieber MR. The basis for the mechanistic bias for deletional over inversional V(D)J recombination. Genes Dev 1992;6:1553-1561.
13. Pannetier C, Even J, Kourilsky P. T-cell repertoire diversity and clonal expansions in normal and clinical samples. Immunol Today 1995;16:176-181.
14. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP): report from an ad hoc subcommittee of the American Academy of neurology AIDS Task Force. Neurology 1991;41:617-618.
15. Hughes R, Bensa S, Willison H, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating pol-yradiculoneuropathy. Ann Neurol 2001;50:195-201. (Pubitemid 32738144)
16. Monteiro J, Hingorani R, Peroglizzi R, et al. Oligoclon-ality of CD81 T cells in multiple sclerosis. Autoimmunity 1996;23:127-138. (Pubitemid 26335868)
17. Schneider-Hohendorf T, Schwab N, Uceyler N, et al. CD81 T-cell immunity in chronic inflammatory demye-linating polyradiculoneuropathy. Neurology 2012;78: 402-408.
18. Khalili-Shirazi A, Gregson NA, Hall MA, et al. T cell receptor V beta gene usage in Guillain-Barré syndrome. J Neurol Sci 1997;145:169-176. (Pubitemid 27121682)
19. Meyer zu HG, Reiners J, Lehmann HC, et al. CD73 is expressed on invading T lymphocytes in the inflamed peripheral nerve. Muscle Nerve 2009;40:287-289.
20. Matsumuro K, Izumo S, Umehara F, et al. Chronic inflammatory demyelinating polyneuropathy: histological and immunopathological studies on biopsied sural nerves. J Neurol Sci 1994;127:170-178. (Pubitemid 24380164)
21. Posnett DN, Sinha R, Kabak S, et al. Clonal populations of T cells in normal elderly humans: the T cell equivalent to "benign monoclonal gammapathy." J Exp Med 1994;179:609-618.
22. Schwab R, Szabo P, Manavalan JS, et al. Expanded CD41 and CD81 T cell clones in elderly humans. J Immunol 1997;158:4493-4499. (Pubitemid 127483955)
23. Lünemann JD, Tackenberg B, Stein A, et al. Dysregulated Epstein-Barr virus infection in patients with CIDP. J Neuroimmunol 2010;218:107-111.
24. Vanderlugt CJ, Miller SD. Epitope spreading. Curr Opin Immunol 1996;8:831-836. (Pubitemid 27007649)
25. Anthony RM, Kobayashi T, Wermeling F, et al. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature 2011;475:110-113.
26. Jacob S, Rajabally YA. Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies. Curr Neuropharmacol 2009;7:337-342.
27. Maddur MS, Othy S, Hegde P, et al. Immunomodulation by intravenous immunoglobulin: role of regulatory T cells. J Clin Immunol 2010;30(suppl 1):S4-S8.
28. Pashov A, Bellon B, Kaveri SV, et al. A shift in encepha-litogenic T cell cytokine pattern is associated with suppression of EAE by intravenous immunoglobulins (IVIg). Mult Scler 1997;3:153-156. (Pubitemid 27390392)
29. Grosse-Wilde H, Blasczyk R, Westhoff U. Soluble HLA class I and class II concentrations in commercial immuno-globulin preparations. Tissue Antigens 1992;39:74-77.
30. Hurez V, Kaveri SV, Mouhoub A, et al. Anti-CD4 activity of normal human immunoglobulin G for therapeutic use (intravenous immunoglobulin, IVIg). Ther Immunol 1994;1:269-277. (Pubitemid 24344443)
31. Marchalonis JJ, Kaymaz H, Dedeoglu F, et al. Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta chain. Proc Natl Acad Sci USA 1992; 89:3325-3329.
32. Pires AE, Afonso AF, Queiros A, et al. Treatment with polyclonal immunoglobulin during T-cell reconstitution promotes naive T-cell proliferation. J Immunother 2010; 33:618-625.
33. Wu CJ, Chillemi A, Alyea EP, et al. Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hema-topoietic chimerism. Blood 2000;95:352-359. (Pubitemid 30017264)
34. Venturi V, Kedzierska K, Turner SJ, et al. Methods for comparing the diversity of samples of the T cell receptor repertoire. J Immunol Methods 2007;321:182-195. (Pubitemid 46441208)
35. Rempala GA, Seweryn M, Ignatowicz L. Model for comparative analysis of antigen receptor repertoires. J Theor Biol 2011;269:1-15.
36. Long SA, Khalili J, Ashe J, et al. Standardized analysis for the quantification of Vbeta CDR3 T-cell receptor diversity. J Immunol Methods 2006;317:100-113. (Pubitemid 44816324)